MX2021014477A - In-situ gelling nanoemulsion of brinzolamide. - Google Patents

In-situ gelling nanoemulsion of brinzolamide.

Info

Publication number
MX2021014477A
MX2021014477A MX2021014477A MX2021014477A MX2021014477A MX 2021014477 A MX2021014477 A MX 2021014477A MX 2021014477 A MX2021014477 A MX 2021014477A MX 2021014477 A MX2021014477 A MX 2021014477A MX 2021014477 A MX2021014477 A MX 2021014477A
Authority
MX
Mexico
Prior art keywords
brinzolamide
nanoemulsion
situ gelling
pharmaceutical
ophthalmic compositions
Prior art date
Application number
MX2021014477A
Other languages
Spanish (es)
Inventor
Sajeev Chandran
Hemant Hanumant Bhalerao
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MX2021014477A publication Critical patent/MX2021014477A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention relates to a pharmaceutical in-situ gelling nanoemulsion ophthalmic compositions of brinzolamide and/or in combination with other active ingredients. The invention provides a pharmaceutical in-situ gelling nanoemulsion ophthalmic compositions comprising brinzolamide, an oil dispersed in an aqueous phase, a primary and/or a secondary surfactant and a thickener.
MX2021014477A 2019-05-29 2020-05-28 In-situ gelling nanoemulsion of brinzolamide. MX2021014477A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921021265 2019-05-29
PCT/IB2020/055052 WO2020240451A1 (en) 2019-05-29 2020-05-28 In-situ gelling nanoemulsion of brinzolamide

Publications (1)

Publication Number Publication Date
MX2021014477A true MX2021014477A (en) 2022-01-06

Family

ID=71670310

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014477A MX2021014477A (en) 2019-05-29 2020-05-28 In-situ gelling nanoemulsion of brinzolamide.

Country Status (2)

Country Link
MX (1) MX2021014477A (en)
WO (1) WO2020240451A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023538075A (en) * 2020-08-17 2023-09-06 ヒューマンウェル ファーマシューティカル ユーエス Long acting in situ forming/gelling composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378703A (en) 1990-04-09 1995-01-03 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
US6071904A (en) 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
KR20170120161A (en) * 2015-03-05 2017-10-30 알러간, 인코포레이티드 Self-emulsifying drug delivery system (SEDDS) for ophthalmic drug delivery
US20190008920A1 (en) * 2017-05-19 2019-01-10 Ocugen, Inc. Ophthalmic compositions and methods of use

Also Published As

Publication number Publication date
WO2020240451A1 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
PH12020550622A1 (en) Kras g12c inhibitors
AU2018263868A1 (en) Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
MX2021013581A (en) Nanoemulsion compositions comprising biologically active ingredients.
WO2017100063A3 (en) Stable ready-to-drink beverage compositions comprising lipophilic active agents
ZA201906011B (en) Apoptosis-inducing agents
MX2023008031A (en) Gcn2 inhibitors and uses thereof.
MX2023011657A (en) Compositions comprising curons and uses thereof.
MX2019013070A (en) Improved cleansing compositions.
MX2018010788A (en) Ophthalmological composition.
MX2021011297A (en) Oral care compositions for active agent delivery.
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
PH12017502322A1 (en) Therapeutic agent for fibrosis
ZA202102702B (en) Synergistic disinfectant compositions having enhanced antimicrobial efficacy and stability, and methods of using the same
PH12021550033A1 (en) Tumor reduction formulations and methods of use thereof
MX2021014477A (en) In-situ gelling nanoemulsion of brinzolamide.
PH12019502145A1 (en) Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
MX2021000314A (en) Tumor reduction formulations and methods of use thereof.
PH12018502343B1 (en) Oil-in-water emulsion containing wheat flour and physically modified starch
PH12018502524A1 (en) Physiologically balanced injectable formulations of fosnetupitant
PH12018000227B1 (en) A pharmaceutical composition for improving or preventing progression of chronic kidney disease
BR112022004677A2 (en) Ophthalmic composition for the treatment of uveitis
MX2019010618A (en) Pharmaceutical ophthalmic compositions, preparation processes, and uses thereof.
WO2020123753A3 (en) Anellosomes for delivering intracellular therapeutic modalities
MX2020003513A (en) Active ingredient compositions comprising n-alkenoyl-n-alkylgluca mides and the use thereof.
AU2017256125A1 (en) Oral composition